# EviCure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evicure

- Industry: Medical Devices & Equipment
- Headquarters: Ness Ziona, Israel
- Website: www.evicure.bio/
- Total disclosed funding: $0.1M
- Latest round: Seed (May 1, 2026)
- Investors on record: 1

## About

EviCure Ltd., located in Ness Ziona, Israel, specializes in developing innovative anti-cancer precision therapies using advanced extracellular vesicles technology to address critical oncology needs.Founded in 2023 in Ness Ziona, Israel, EviCure Ltd. focuses on anti-cancer therapies, particularly for refractory non-small cell lung cancer (NSCLC). The company has completed 3 deals, with the most recent funding round on September 15, 2025, indicating active development in its business strategy. EviCure is not known to have any subsidiaries, nor was it formed through a merger. The founder's history is not detailed, but the company is positioned for growth in the oncology sector.EviCure specializes in anti-cancer precision therapies, leveraging innovative technologies centered around extracellular vesicles (EVs). Their flagship product, PL-Ex1, is an EV-based treatment specifically designed for refractory non-small cell lung cancer (NSCLC), addressing critical unmet medical needs in oncology. The company focuses on the discovery and application of the unique molecular cargo found within stem cells and EV subpopulations, which exhibit selective therapeutic effects and superior anti-tumor activity. These products are intended for healthcare providers and clinical research institutions involved in cancer treatment, primarily targeting markets in Europe, North America, and Asia, where the prevalence of solid cancers is rising. EviCure's offerings are rooted in rigorous scientific research and validation, aimed at enhancing the efficacy and precision of cancer therapies for patients worldwide.EviCure's revenue structure is built on a business-to-business (B2B) model, targeting partnerships with hospitals, research institutions, and pharmaceutical companies interested in advanced cancer treatments. The company generates income through the sale of its trademarked product, PL-Ex1, alongside potential future offerings derived from their extensive research on EV libraries and AI technology. Each transaction typically involves agreements for the distribution of their products, potentially supplemented by collaborative research initiatives aimed at further developing their therapeutic solutions. The pricing structure for PL-Ex1 and subsequent products is tailored to accommodate institutional clients, reflecting the specialized nature of their offerings and the complexity inherent in cancer treatment solutions. As the global cancer therapy market expands, EviCure is positioned to capitalize on increasing demand for targeted therapies, enhancing both their market presence and revenue potential.EviCure aims to enhance its product lineup with new therapeutics targeting solid tumors, with plans for upcoming releases in the next two years. The company is focused on expanding its reach into additional European and Asian markets by 2026, leveraging its recent funding from Peregrine Ventures, raised in September 2025, to support these initiatives. This funding will be pivotal in scaling operations and accelerating product development efforts.

## Funding rounds

- Seed, May 1, 2026, $0.1M — Peregrine Ventures
- Seed, Sep 15, 2025 — Peregrine Ventures
- Seed, Apr 1, 2025 — Peregrine Ventures
- Seed, Mar 31, 2024 — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed